ChromaDex to Present at the ICR Conference 2017 on January 11, 2017
January 04 2017 - 6:30AM
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health,
wellness and nutritional ingredients, that creates science-based
solutions for dietary supplement, food and beverage, skin care,
sports nutrition, and pharmaceutical products, announced today that
its Chief Executive Officer and Founder, Frank Jaksch, will present
at the ICR Conference 2017. The conference will be held January
9-11, 2017, at the JW Marriott Orlando Grande Lakes in Orlando,
Florida.
Mr. Jaksch is scheduled to present on Wednesday, January 11,
2017, at 11:30 a.m. Eastern Time. ChromaDex management will also
attend one-on-one meetings with institutional investors throughout
the day.
About ChromaDex:
ChromaDex leverages its complementary business units to
discover, acquire, develop and commercialize patented and
proprietary ingredient technologies that address the dietary
supplement, food, beverage, skin care and pharmaceutical markets.
In addition to our ingredient technologies unit, we also have
business units focused on natural product fine chemicals (known as
"phytochemicals"), chemistry and analytical testing services, and
product regulatory and safety consulting (known as Spherix
Consulting). As a result of our relationships with leading
universities and research institutions, we are able to discover and
license early stage, IP-backed ingredient technologies. We then
utilize our in-house chemistry, regulatory and safety consulting
business units to develop commercially viable ingredients. Our
ingredient portfolio is backed with clinical and scientific
research, as well as extensive IP protection. Our portfolio of
patented ingredient technologies includes NIAGEN® nicotinamide
riboside; pTeroPure® pterostilbene; PURENERGY®, a
caffeine-pTeroPure® co-crystal; IMMULINA™, a spirulina extract; and
AnthOrigin™, anthocyanins derived from a domestically-produced,
water-extracted purple corn. To learn more about ChromaDex, please
visit www.ChromaDex.com.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended. Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects",
"anticipates", "intends", "estimates", "plans", "potential",
"possible", "probable", "believes", "seeks", "may", "will",
"should", "could" or the negative of such terms or other similar
expressions. Actual results may differ materially from those set
forth in this release due to the risks and uncertainties inherent
in ChromaDex's business. More detailed information about ChromaDex
and the risk factors that may affect the realization of
forward-looking statements is set forth in ChromaDex's Annual
Report on Form 10-K for the fiscal year ended January 2, 2016,
ChromaDex's Quarter Reports on Form 10-Q and other filings
submitted by ChromaDex to the SEC, copies of which may be obtained
from the SEC's website at www.sec.gov. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. All forward-looking statements
are qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
ChromaDex Media Contact:
Breah Ostendorf
Marketing Director
949-537-4103
BreahO@chromadex.com
ChromaDex Investor Contact:
Andrew Johnson
Director of Investor Relations
949-419-0288
AndrewJ@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024